United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $518.74, for a total value of $4,928,030.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $168,301,561.82. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Up 2.7%

UTHR traded up $13.93 on Thursday, hitting $532.94. 992,945 shares of the company traded hands, compared to its average volume of 490,031. United Therapeutics Corporation has a 12-month low of $292.34 and a 12-month high of $609.35. The company has a 50 day moving average of $540.37 and a 200-day moving average of $533.71. The stock has a market capitalization of $22.62 billion, a PE ratio of 19.67, a PEG ratio of 1.73 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $6.41 EPS. On average, research analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arjuna Capital boosted its position in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC increased its position in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC increased its position in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analyst support remained strong. H.C. Wainwright reiterated its Buy rating and maintained a $660 price target, citing United Therapeutics’ diversified pipeline as a counterbalance to near-term headwinds. Buy Rating Reiterated on United Therapeutics as Diversified Pipeline Offsets Near-Term Headwinds
• Positive Sentiment: Second-quarter EPS beat expectations. United Therapeutics reported earnings of $7.27 per share, above the roughly $6.82–$6.86 analyst consensus and up from $6.41 a year earlier. The company also posted a 40.62% net margin, supporting the stock’s valuation. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Pipeline developments improved the longer-term outlook. Management highlighted regulatory submissions and continued progress for ralinepag and Tyvaso-related programs. Analysts view these products as potential future growth drivers that could diversify the company beyond its existing pulmonary arterial hypertension therapies. United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Royal Bank of Canada lowered its price target from $704 to $677 but retained an Outperform rating, still implying substantial potential upside from recent trading levels. The reduction signals more cautious near-term assumptions rather than a change to the overall bullish view. Benzinga
• Negative Sentiment: Revenue missed estimates and declined year over year. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down about 2% from the prior year. Competitive pressure and concerns surrounding Tyvaso are the primary near-term operating headwinds. United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
• Negative Sentiment: CEO Martine Rothblatt sold approximately $4.9 million of stock. The sale reduced her direct holdings by 2.84%, potentially weighing modestly on sentiment, although she continues to own a substantial position. United Therapeutics CEO Stock Sale Filing

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada lowered their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.